

November 16, 2025

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30 read with Schedule III of the Listing Regulations, this is to inform you that the Mankind Pharma Limited (“Company”) has received an order for Financial Year 2018-19 & 2019-20, on November 15, 2025 from Office of the Assistant Commissioner, Cuttack (“Department”), in respect of erstwhile M/s Lifestar Pharma Private Limited, a wholly owned subsidiary of the Company which now stands merged with the Company, under the applicable provisions of the GST Act.

Based on the assessment of facts and prevailing law, the Company is of the view that the aforesaid order is arbitrary and unjustified. The Company will file necessary appeal with the appellate authority in this regard. There is no material impact on financials, operations or other activities of the Company.

The detailed disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as **Annexure-I**.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Annexure-I

Disclosure as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No.	Particulars of Information required to be provided	Details
1	Name of the authority	Assistant Commissioner, GST & Central Excise, Cuttack ("Department")
2	Nature and details of the action(s) taken, initiated or order(s) passed	The Company has received an Order, in respect of erstwhile M/s Lifestar Pharma Private Limited, a wholly owned subsidiary of the Company which now stands merged with the Company from the Odisha GST Authority imposing penalty of INR 22,16,148/- under applicable provisions of the CGST Act, 2017, SGST Act, 2017 and IGST Act, 2017 for Financial Year 2018-19 & 2019-20.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	November 15, 2025
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	The Order has been passed on the contention that there is an alleged mismatch in the ITC figures reported in the GST return.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	<p>Based on the assessment of facts and prevailing law, the Company is of the view that the demand including penalty levied is arbitrary and unjustified.</p> <p>The Company does not agree with the order and will take appropriate action(s) for the same including filing of an appeal if required.</p> <p>There is no material impact on the company's financials, operations, or other activities.</p>

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com